proLékaře.cz | 6.11.2026



# Forum diabetologicum 2013; 2

## Regisler kľúčových slov


| kľúčové slovo | (číslo): strany |
|---|---|
| akútne srdcové zlyhávanie | (1): 23–26 |
| akútny koronárny syndróm | (1): 23–26 |
| aliskirén | (1): 11–17 |
| antiagregační léčba | (2): 68–73 |
| antidiabetiká | (1): 18–22 |
| antihypertenzívne lieky | (1): 11–17 |
| anti-VEGF | (3): 185–188 |
| AT1-blokátory | (2): 68–73 |
| aterogénna dyslipidémia | (2): 140–145 |
| ateroskleróza | (2): 140–145 |
| autonómna neuropatia | (2): 108–116 |
| bazálne analógy inzulínu | (2): 130–139 |
| cievy | (2): 90–97 |
| cílová hodnota krevního tlaku | (2): 68–73 |
| časná inzulinová terapie diabetu 2. typu | (3): 165–168 |
| časná kombinační léčba | (3): 165–168 |
| časná léčba diabetu | (3): 165–168 |
| dermoepidermálne štepy | (2): 98–101 |
| diabetes mellitus | (1): 18–22 |
| | (1): 23–26 |
| | (1): 27–30 |
| | (1): 31–35 |
| | (1): 36–40 |
| | (2): 102–107 |
| | (2): 108–116 |
| | (2): 117–121 |
| | (3): 190–192 |
| diabetes mellitus 1. typu | (3): 185–188 |
| diabetes mellitus 2. typu | (2): 122–124 |
| diabetes mellitus-výskyt | (3): 193–199 |
| diabetická kardiomyopatia | (1): 18–22 |
| diabetická nefropatia | (1): 31–35 |
| | (2): 117–121 |
| | (S1): 1–6 |
| diabetická noha | (2): 74–83 |
| | (2): 90–97 |
| | (2): 98–101 |
| diabetická retinopatia | (3): 170–175 |
| | (3): 176–180 |
| | (3): 181–184 |
| | (3): 193–199 |
| diabetické ulcerace | (2): 102–107 |
| diabetický edém makuly | (3): 170–175 |
| | (3): 185–188 |
| | (3): 193–199 |
| diagnostika diabetickej nefropatie | (2): 117–121 |
| dysliporoteinémia | (2): 140–145 |
| endovaskulárne výkony | (2): 90–97 |
| etiopatogenéza | (2): 84–89 |
| glaukóm | (3): 190–192 |

| kľúčové slovo | (číslo): strany |
|---|---|
| gliptíny | (2): 130–139 |
| gravidita | (3): 176–180 |
| | (3): 181–184 |
| hypertriacylglycerolémie | (2): 140–145 |
| hypolipidemika | (2): 68–73 |
| chronická rana | (2): 98–101 |
| indikačné obmedzenia | (2): 130–139 |
| inhibitory ACE | (2): 68–73 |
| intenzifikovaný inzulínový režim | (2): 122–124 |
| inzulín lispro mix | (2): 122–124 |
| jednoduchosť a finančná nenáročnosť | (2): 98–101 |
| kardiorenálny syndróm | (1): 31–35 |
| kardiovaskulárne ochorenia | (1): 27–30 |
| kardiovaskulární mortalita | (2): 102–107 |
| kardiovaskulární riziko | (3): 165–168 |
| komorová fibrilácia | (1): 36–40 |
| kompliancia | (1): 11–17 |
| komplikácie | (2): 108–116 |
| larvoterapia | (2): 74–83 |
| laserová liečba | (3): 176–180 |
| léčba prediabetu | (3): 165–168 |
| liečba pomocou živých bunkových línií | (2): 74–83 |
| liečba riadeným podtlakom | (2): 74–83 |
| mikroalbuminúria | (2): 117–121 |
| mikroalbuminurie | (2): 68–73 |
| multiorgánovomultivaskulárna choroba | (1): 36–40 |
| nefroprotekce | (2): 68–73 |
| neovaskularizácie terča zrakového nervu | (3): 185–188 |
| neovaskulárny glaukóm | (3): 190–192 |
| pars plana vitrektómia | (3): 170–175 |
| periférna neuropatia | (2): 108–116 |
| podiatrické centrum | (2): 102–107 |
| prediabetes | (3): 165–168 |
| predsieňová fibrilácia | (1): 27–30 |
| premixované inzulínové analógy | (2): 122–124 |
| prevence diabetu | (3): 165–168 |
| primárny glaukóm s otvoreným uhlom | (3): 190–192 |
| ranibizumab | (3): 185–188 |
| rehospitalizácie pre akútne ochorenia | (1): 23–26 |
| rizikové faktory | (2): 84–89 |
| skríning | (3): 176–180 |
| srdcové zlyhávanie | (1): 18–22 |
| syndróm diabetickej nohy | (2): 84–89 |
| tehotenstvo | (3): 181–184 |
| tlak vnutroočný | (3): 190–192 |
| tolerancia | (1): 11–17 |
| transplantácia autológnych štepov | (2): 98–101 |
| trvanie účinku | (1): 11–17 |
| zobrazovacie metódy | (2): 90–97 |

proLékaře.cz | 6.11.2026



# Forum diabetologicum 2013; 2

## Index of key words


| key word | (číslo): strany |
|---|---|
| ACE inhibitors | (2): 68–73 |
| acute coronary syndrome | (1): 23–26 |
| acute heart failure | (1): 23–26 |
| aliskiren | (1): 11–17 |
| angiotensin receptor blockers | (2): 68–73 |
| antidiabetics | (1): 18–22 |
| antihypertensive drugs | (1): 11–17 |
| antiplatelet therapy | (2): 68–73 |
| anti-VEGF | (3): 185–188 |
| atherogenic dyslipidemia | (2): 140–145 |
| atherosclerosis | (2): 140–145 |
| atrial fibrilation | (1): 27–30 |
| autonomic neuropathy | (2): 108–116 |
| basal insulin analogues | (2): 130–139 |
| blood vessels | (2): 90–97 |
| cardiorenal syndrome | (1): 31–35 |
| cardiovascular disease | (1): 27–30 |
| cardiovascular mortality | (2): 102–107 |
| cardiovascular risk | (3): 165–168 |
| compliance | (1): 11–17 |
| complications | (2): 108–116 |
| dermoepidermal skin grafts | (2): 98–101 |
| diabetes mellitus | (1): 18–22 |
| | (1): 23–26 |
| | (1): 27–30 |
| | (1): 31–35 |
| | (1): 36–40 |
| | (2): 102–107 |
| | (2): 108–116 |
| | (2): 117–121 |
| | (3): 190–192 |
| diabetes mellitus type 1 | (3): 185–188 |
| diabetes mellitus type 2 | (2): 122–124 |
| diabetes mellitus-incidence | (3): 193–199 |
| diabetes prevention | (3): 165–168 |
| diabetic cardiomyopathy | (1): 18–22 |
| diabetic foot | (2): 74–83 |
| | (2): 90–97 |
| | (2): 98–101 |
| diabetic foot clinic | (2): 102–107 |
| diabetic foot syndrome | (2): 84–89 |
| diabetic foot ulcer | (2): 102–107 |
| diabetic macular edema | (3): 170–175 |
| | (3): 185–188 |
| | (3): 193–199 |
| diabetic nephropathy | (1): 31–35 |
| | (2): 117–121 |
| | (S1): 1–6 |
| diabetic retinopathy | (3): 170–175 |
| | (3): 176–180 |
| | (3): 181–184 |
| | (3): 193–199 |
| diagnosis of diabetic nephropathy | (2): 117–121 |
| duration of action | (1): 11–17 |
| dyslipoproteinemia | (2): 140–145 |
| early combination treatment | (3): 165–168 |
| early insulin treatment in type 2 diabetes | (3): 165–168 |
| early treatment of diabetes | (3): 165–168 |
| endovascular intervention | (2): 90–97 |
| etiopathogenesis | (2): 84–89 |
| forgiveness | (1): 11–17 |
| glaucoma | (3): 190–192 |
| gliptines | (2): 130–139 |
| goal blood pressure | (2): 68–73 |
| heart failure | (1): 18–22 |
| hypertriglyceridemia | (2): 140–145 |
| chronical wound | (2): 98–101 |
| imaging methods | (2): 90–97 |
| indicating restrictions | (2): 130–139 |
| insulin lispro mix | (2): 122–124 |
| intensified insulin regimen | (2): 122–124 |
| intraocular pressure | (3): 190–192 |
| laser treatment | (3): 176–180 |
| lipid-lowering drugs | (2): 68–73 |
| maggot therapy | (2): 74–83 |
| microalbuminuria | (2): 68–73 |
| | (2): 117–121 |
| multiorganomultivascular arterial disease | (1): 36–40 |
| neovascular glaucoma | (3): 190–192 |
| nephroprotection | (2): 68–73 |
| optic disc neovascularization | (3): 185–188 |
| pars plana vitrektómia | (3): 170–175 |
| peripheral neuropathy | (2): 108–116 |
| prediabetes | (3): 165–168 |
| prediabetes treatment | (3): 165–168 |
| pregnancy | (3): 176–180 |
| | (3): 181–184 |
| premixed insulin analogues | (2): 122–124 |
| primary open-angle glaucoma POAG | (3): 190–192 |
| ranibizumab | (3): 185–188 |
| rehospitalization for acute diseases | (1): 23–26 |
| risk factors | (2): 84–89 |
| screening | (3): 176–180 |
| simplicity and low cost | (2): 98–101 |
| transplatation of autolog skin grafts | (2): 98–101 |
| treatment with controlled vacuum | (2): 74–83 |
| treatment with live cell lines | (2): 74–83 |
| ventricular fibrilation | (1): 36–40 |